• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa.

作者信息

Megna Matteo, Ruggiero Angelo, Di Guida Adriana, Patrì Angela, Fabbrocini Gabriella, Marasca Claudio

机构信息

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.

出版信息

Dermatol Ther. 2020 Jul;33(4):e13756. doi: 10.1111/dth.13756. Epub 2020 Jun 29.

DOI:10.1111/dth.13756
PMID:32495491
Abstract
摘要

相似文献

1
Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa.司库奇尤单抗：治疗银屑病和化脓性汗腺炎的有效药物。
Dermatol Ther. 2020 Jul;33(4):e13756. doi: 10.1111/dth.13756. Epub 2020 Jun 29.
2
Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.古塞库单抗治疗化脓性汗腺炎、银屑病和克罗恩病。
J Dermatolog Treat. 2021 Mar;32(2):261-263. doi: 10.1080/09546634.2019.1654067. Epub 2019 Aug 25.
3
Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.病例报告：采用不同治疗方法治疗化脓性汗腺炎和银屑病共存。
F1000Res. 2019 Nov 26;8:2002. doi: 10.12688/f1000research.21216.2. eCollection 2019.
4
A case of hidradenitis suppurativa successfully treated with apremilast in a patient with psoriasis and SAMPUS.一例化脓性汗腺炎患者同时患有银屑病和头皮穿凿性蜂窝织炎，使用阿普米拉斯成功治疗。
Dermatol Ther. 2020 May;33(3):e13448. doi: 10.1111/dth.13448. Epub 2020 May 8.
5
Ixekizumab in hidradenitis suppurativa in a psoriatic patient.司库奇尤单抗治疗一名银屑病患者的化脓性汗腺炎
G Ital Dermatol Venereol. 2020 Dec;155(6):788-789. doi: 10.23736/S0392-0488.18.06135-7. Epub 2019 Jan 9.
6
Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.用阿达木单抗治疗重度顽固性化脓性汗腺炎。
J Dtsch Dermatol Ges. 2009 Feb;7(2):139-41. doi: 10.1111/j.1610-0387.2008.06918.x.
7
Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa.阿达木单抗诱发的矛盾性脓疱型银屑病和脱发在一名患有化脓性汗腺炎的患者中用司库奇尤单抗成功治疗。
J Dermatolog Treat. 2023 Dec;34(1):2256905. doi: 10.1080/09546634.2023.2256905.
8
Psoriasis Onset during Anti-TNF Treatment for Hidradenitis Suppurativa: Successful Remission of Both Conditions with Secukinumab.化脓性汗腺炎抗TNF治疗期间银屑病发病：司库奇尤单抗成功缓解两种病症。
Skinmed. 2023 Mar 29;21(1):57-58. eCollection 2023.
9
High placebo rates in clinical trials: Is the problem scoring systems or drug efficacy?临床试验中高安慰剂率：问题在于评分系统还是药物疗效？
J Am Acad Dermatol. 2020 Dec;83(6):e431. doi: 10.1016/j.jaad.2020.07.040. Epub 2020 Jul 17.
10
Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)-syndrome: a new entity within the spectrum of autoinflammatory syndromes?坏疽性脓皮病、痤疮、银屑病、关节炎和化脓性汗腺炎（PAPASH）综合征：自身炎症性综合征范围内的一种新实体？
J Eur Acad Dermatol Venereol. 2016 Jan;30(1):141-3. doi: 10.1111/jdv.12631. Epub 2014 Jul 28.

引用本文的文献

1
Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.化脓性汗腺炎：生物制剂和小分子免疫调节治疗综述
J Cutan Med Surg. 2025 Jan-Feb;29(1):NP1-NP20. doi: 10.1177/12034754241300292. Epub 2024 Nov 27.
2
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
3
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.
深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
4
Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report.慢性化脓性汗腺炎并发高级别鳞状细胞癌，使用西米普利单抗成功治疗：一例报告
Case Rep Dermatol. 2023 Feb 14;15(1):35-39. doi: 10.1159/000525347. eCollection 2023 Jan-Dec.
5
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience.阿达木单抗、优特克单抗和司库奇尤单抗治疗化脓性汗腺炎：真实世界经验综述
Clin Cosmet Investig Dermatol. 2023 Jan 19;16:135-148. doi: 10.2147/CCID.S391356. eCollection 2023.
6
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
7
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.古塞库单抗、司库奇尤单抗和替拉珠单抗治疗银屑病的真实世界证据综述
Clin Cosmet Investig Dermatol. 2022 Aug 16;15:1649-1658. doi: 10.2147/CCID.S364640. eCollection 2022.
8
An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series.抗白细胞介素-17A单克隆抗体司库奇尤单抗治疗难治性化脓性汗腺炎：病例系列
Skin Appendage Disord. 2022 Jul;8(4):342-345. doi: 10.1159/000521860. Epub 2022 Feb 9.
9
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.依奇珠单抗与布罗达单抗治疗中重度银屑病的间接比较：一项意大利单中心真实世界回顾性研究的结果
Dermatol Ther. 2022 Sep;35(9):e15667. doi: 10.1111/dth.15667. Epub 2022 Jul 11.
10
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.IL-17A 是中重度化脓性汗腺炎的一个有针对性的治疗靶点：临床前和 II 期概念验证研究的综合结果。
Exp Dermatol. 2022 Oct;31(10):1522-1532. doi: 10.1111/exd.14619. Epub 2022 Aug 19.